Home > Healthcare > Pharmaceuticals > Finished Drug Form > Interleukin Inhibitors Market

Interleukin Inhibitors Market Trends

Report ID: GMI10044
Published Date: Jun 2024
Report Format: PDF

Download Free Sample

Interleukin Inhibitors Market Trends

Increased investments in research and development (R&D) have resulted in the discovery of innovative therapies and advanced treatment options. These efforts have also propelled advancements in biologic therapy agents and precision medicine approaches, addressing the diverse needs of patients with interleukin inhibitors, thereby driving market expansion.

For instance, in March 2024, Acelyrin, Inc. revealed promising outcomes from its global phase 2b/3 clinical trial of izokibep, a potential breakthrough in psoriatic arthritis treatment. Izokibep, a small protein therapeutic targeting IL-17A presented remarkable potency, strong tissue penetration capabilities, and an extended half-life. Thus, the availability of a strong product pipeline and associated treatment for broader applications will spur market growth.

Moreover, the increasing aging population with autoimmune diseases, advancements in diagnostic technologies, supportive government healthcare policies, and strategic expansions by major industry players further drives the market demand.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Interleukin inhibitors industry size was worth USD 24.3 billion in 2023 and will grow at a 12% CAGR between 2024 and 2032, driven by escalating incidences of autoimmune disorders like rheumatoid arthritis and psoriasis.

The psoriasis segment will record 11.9% CAGR through 2032, primarily due to increasing prevalence of the chronic skin condition and ongoing research into the immunopathogenesis of psoriasis.

U.S. interleukin inhibitors industry achieved USD 9.3 billion in 2023, propelled by the region's advanced healthcare infrastructure and rise in research and development activities.

Some of the prominent interleukin inhibitors industry players are AbbVie Inc., Biogen, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Fujifilm Kyowa Kirin Biologics Co., Ltd., Genentech USA, Inc., Janssen Pharmaceutical Companies (Johnson and Johnson), Novartis AG, Regeneron Pharmaceuticals, Inc., and Sanofi, among others.